En

Onkocare

Onkocare Life Technology (Suzhou) Co., Ltd. is a high-tech enterprise that focuses on the development of molecular diagnostic products for all types of cancer using internationally leading tumor marker mining technology and DNA methylation hypersensitivity detection technology. The company is located in Suzhou High tech Zone (Jiangsu Medical Device Industry Park). After more than 4 years of rapid development, it has become a high-quality "IVD+" enterprise that integrates "raw material production+reagent research and development+instrument support+bioinformatics analysis+testing services".

Onkocare has three subsidiaries and established a group style layout with research and development of cancer molecular diagnostic reagents as the core, bioinformatics analysis technology platform, and third-party medical testing as the focus, committed to becoming a leading enterprise in the field of cancer molecular diagnosis.

  • Corporate Vision

    Becoming the People's First Choice for Anti Cancer

  • Corporate mission

    Gene technology benefits people's livelihoods

  • Values

    Embracing Embroidery, Pragmatism, and Innovation

  • 2014-2017

    • Breakthroughs in research in the field of tumor genomics
    • Complete DNA methylation technology precipitation and initiate big data system development project


  • 2018

    • Nanjing Onkocare was established and completed angel round financing of 4.8 million yuan
    • Establish a standard molecular biology laboratory
    • Complete the preliminary finalization of the original research technical plan

  • 2019✮

    • Onkocare's headquarters officially settled in Suzhou High tech Zone
    • Completed Pre-A round financing of 15 million yuan
    • The founder was awarded the title of "Leading Entrepreneurial Talent in Suzhou High tech Zone"
    • Initiate patent protection for core technologies
    • Complete the development of a DNA methylation detection product panel

  • 2020

    • Completion and acceptance of GMP clean factories with a scale of over 10 million square meters and a scale of 100000
    • Founder awarded "Leading Talent in Gusu Entrepreneurship"
    • Synchronous promotion of research and development of four DNA methylation detection products

  • 2021

    • Completed Series A and Series A+financing, with a cumulative financing amount of 120 million yuan
    • The third-party medical laboratory under the company has been approved to establish a platform for technology optimization and upgrading, as well as research and development verification of multiple cancer products

  • 2022

    • Complete a comprehensive upgrade of innovative platform technology
    • Three products have entered the research and development stage, started registration and certification, and four first-class products have obtained registration certificates. The platform has optimized technology and won awards in the National Disruptive Technology Innovation Competition
    • Completed the Jiangsu Province Major Disease Biological Sample Bank Project - Identification of Non invasive Early Screening Markers for Lung Cancer Based on Liquid Phase Biopsy
    • Assist the government COVID-19 screening, and detect more than 30 million people in total

  • 2023

    • One product enters clinical trials, two products initiate registration testing
    • Awarded the title of "National High tech Enterprise"✮
    • Awarded the title of "Jiangsu Province Gene Testing and Tumor Diagnosis Engineering Research Center"
    • Establish an innovative base for tumor molecular diagnostic medicine transformation at Jiangsu Research Hospital College

Qualification certificate
Social honors
Qualification certificate
Social honors
Social responsibility
Since its establishment, Onkocare has been committed to developing cancer early screening and testing products that are affordable for the public, with the aim of giving back to society, fulfilling the obligation of being a corporate citizen, and winning support and respect.

ONKOCARE